Quick Answer
Syndax Pharmaceuticals Inc reported Net Income Loss of -$285.42 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed an increase of +10.5% in Net Income Loss from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$10.33 million | Q2 2016: -$8.36 million | Q3 2016: -$14.97 million | Q4 2016: -$10.82 million | Q1 2017: -$12.97 million | Q2 2017: -$13.64 million | Q3 2017: -$15.09 million | Q4 2017: -$19.10 million | Q1 2018: -$19.40 million | Q2 2018: -$18.39 million | Q3 2018: -$17.34 million | Q4 2018: -$18.84 million | Q1 2019: -$14.30 million | Q2 2019: -$14.92 million | Q3 2019: -$12.83 million | Q4 2019: -$14.00 million | Q1 2020: -$15.24 million | Q2 2020: -$17.06 million | Q3 2020: -$20.44 million | Q4 2020: -$20.42 million | Q1 2021: -$27.72 million | Q2 2021: -$22.91 million | Q3 2021: -$20.64 million | Q1 2022: -$37.17 million | Q2 2022: -$37.57 million | Q3 2022: -$35.40 million | Q1 2023: -$41.13 million | Q2 2023: -$44.62 million | Q3 2023: -$51.15 million | Q1 2024: -$72.40 million | Q2 2024: -$68.06 million | Q3 2024: -$84.13 million | Q1 2025: -$84.85 million | Q2 2025: -$71.85 million | Q3 2025: -$60.72 million.
- Over the full 12 years of available data (2014 to 2025), Syndax Pharmaceuticals Inc's Net Income Loss has declined by 1,339.5%.
- Historical annual values: Fiscal year 2025: -$285.42 million | Fiscal year 2024: -$318.76 million | Fiscal year 2023: -$209.36 million | Fiscal year 2022: -$149.34 million | Fiscal year 2021: $24.93 million | Fiscal year 2020: -$73.16 million | Fiscal year 2019: -$56.05 million | Fiscal year 2018: -$73.96 million | Fiscal year 2017: -$60.80 million | Fiscal year 2016: -$44.47 million | Fiscal year 2015: -$24.12 million | Fiscal year 2014: -$19.83 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: